Insmed’s Brensocatib Receives the US FDA’s Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis

 Insmed’s Brensocatib Receives the US FDA’s Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis

Insmed Receives FDA Approval of Arikayce to Treat Mycobacterium Avium Complex (MAC) Lung Disease in Adults

Shots:

  • The BTD is based on P-II WILLOW study assessing brensocatib vs PBO in adults with NCFBE for reducing exacerbations
  • Insmed expects to initiate a P-III program for brensocatib in bronchiectasis in the H2’21
  • Brensocatib is a novel oral, reversible DPP1 inhibitor, currently being developed for the treatment of bronchiectasis and other inflammatory diseases

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post